Advertisement
Advertisement
U.S. Markets close in 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4400-0.0600 (-2.40%)
As of 03:22PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5000
Open2.4400
Bid2.4100 x 1000
Ask2.4300 x 3100
Day's Range2.3700 - 2.5800
52 Week Range1.1500 - 5.9900
Volume149,956
Avg. Volume747,027
Market Cap275.686M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

    Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York. A we

  • GlobeNewswire

    DBV Technologies Announces Private Placement Financing of $194 Million

    Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 million private investment in public equity (PIPE) financing (corresponding to €181 million on the basis of an exchange rate of $1.0739 = €1.00 published by the European Central Bank on June 8, 2022) from the sale of 32,855,669

  • GlobeNewswire

    DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

    Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months, compared with 33.5% of subjects in the placebo armPivotal trial met primary endpoint: lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 22.4%, exceeding the pre-specified threshold of 15%Safety results were gene

Advertisement
Advertisement